Overview

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin) at Visit 2, subjects will treat daily with topiramate or during Prodrome with frovatriptan. Subjects complete a 2-month Treatment Period before exit at Visit 3.This study will compare the effectiveness of daily treatment vs. treatment during the pre-headache phase for prevention of migraine.
Phase:
Phase 4
Details
Lead Sponsor:
Clinvest
Collaborator:
Endo Pharmaceuticals
Treatments:
Frovatriptan
Topiramate